Resecabtagene autoleucel

N/A

Report date: 2026/02/18 20:02:09

Base Information

Drug NameResecabtagene autoleucel
Drug Alias Namerese-celCABA-201
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPemphigusScleroderma, SystemicLupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCabaletta Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesCabaletta Bio Inc
Inactive CompaniesN/A
Active IndicationsPemphigusScleroderma, SystemicLupus Erythematosus, Systemic +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A